Physician profile
Ayman E Farid
NPI 1760457113
$28,160.58
in general payments reported to CMS, 2019-2025
17 companies · $435 in 2025
The $435 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,220 · 2020: $2,994 · 2021: $4,028 · 2022: $9,894 · 2023: $3,282 · 2024: $307 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,452 · Travel and Lodging: $1,169 · Consulting Fee: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.64 |
| Travel and Lodging | $1,169.02 |
| Consulting Fee | $404.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $23,684.68 | 2019-2023 | Venacure 1470 Pro |
| Abbott Laboratories | $2,677.25 | 2021-2023 | Optis, Dragonfly Opstar |
| Shockwave Medical, INC | $902.67 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $238.83 | 2019-2022 | |
| Boston Scientific Corporation | $224.12 | 2019-2023 | Opticross |
| Astrazeneca Pharmaceuticals Lp | $105.39 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $63.50 | 2023-2025 | |
| Amgen INC. | $60.82 | 2019-2025 | Repatha, Repatha |
| Heartflow, INC. | $43.64 | 2025 | |
| Medtronic, INC. | $36.82 | 2025 | Corevalve Evolut R |
| Pfizer INC. | $25.26 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $19.08 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $18.69 | 2023 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $17.66 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $15.17 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $13.61 | 2022 | |
| Bardy Diagnostics, INC. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Farid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.